Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium Respimat (5mcg and 10mcg) in COPD
NCT00168831Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2003
- Primary completion
- Jun 2005
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of tiotropium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Change From Baseline in Trough FEV1 at 48 weeks, Saint George's Respiratory Questionnaire (SGRQ) Total Score at 48 weeks and 2 more. Started Feb 2003; status: completed.
02
Drugs
tiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00168831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00168831.